Cutaneous carcinoma is one of the most common neoplasm tumors in the West. Its incidence rate is one of the fastest growing tumors in China. The Krüppel-like factor 6 (KLF6) is a latent tumor suppressor. Decreased KLF6 is related to the occurrence and progression of many cancers in human. Our previous studies have demonstrated that KLF6 was down-regulation in cutaneous malignant melanoma (CMM), and was significant correlated with ulcer, lymph node metastasis and clinical stage, suggesting that KLF6 loss is expected to become a biological indicator of poor prognosis in CMM patients. In this research, we would further study the features of KLF6 in the malignant progression of CMM. The expression of KLF6 was up-regulated by lentivirus infection containing KLF6, and short hairpin RNA (shRNA) was used for knockdown of KLF6 in CMM cells. Western blot, RT-qpcr, CCK8 assay, transwell migration assays, wound healing assay and flow cytometry were used to test the role of KLF6 in the CMM. We found that reduced expression of KLF6 significantly enhanced proliferation, migration and invasion. Moreover, KLF6 induced CMM cell apoptosis and G1 cycle arrest. The decreased KLF6 expression is expected to be a biological indicator of poor prognosis in CMM patients.
{"title":"The Krüppel-like factor 6 represses proliferation and invasion of cutaneous malignant melanoma.","authors":"Yuan-Yuan Li, Qi-Ming Zheng, Nan Zhang, Min Zhang","doi":"10.5114/pjp.2023.132224","DOIUrl":"10.5114/pjp.2023.132224","url":null,"abstract":"<p><p>Cutaneous carcinoma is one of the most common neoplasm tumors in the West. Its incidence rate is one of the fastest growing tumors in China. The Krüppel-like factor 6 (KLF6) is a latent tumor suppressor. Decreased KLF6 is related to the occurrence and progression of many cancers in human. Our previous studies have demonstrated that KLF6 was down-regulation in cutaneous malignant melanoma (CMM), and was significant correlated with ulcer, lymph node metastasis and clinical stage, suggesting that KLF6 loss is expected to become a biological indicator of poor prognosis in CMM patients. In this research, we would further study the features of KLF6 in the malignant progression of CMM. The expression of KLF6 was up-regulated by lentivirus infection containing KLF6, and short hairpin RNA (shRNA) was used for knockdown of KLF6 in CMM cells. Western blot, RT-qpcr, CCK8 assay, transwell migration assays, wound healing assay and flow cytometry were used to test the role of KLF6 in the CMM. We found that reduced expression of KLF6 significantly enhanced proliferation, migration and invasion. Moreover, KLF6 induced CMM cell apoptosis and G1 cycle arrest. The decreased KLF6 expression is expected to be a biological indicator of poor prognosis in CMM patients.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 3","pages":"194-202"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrzej Marszałek, Joanna Bakinowska, Małgorzata Grobelna, Adam Śliwiński
The technique of liquid-based cytology (LBC) is of increasing diagnostic value in non-gynecological cytology. The purpose of the present study was to validate modifications to stages of the LBC process and to assess the diagnostic usefulness of the LBC technique. Between May 2021 and January 2022, a total of 484 samples were prepared from routine cytology tests carried out in the Department of Tumor Pathology of The Greater Poland Cancer Center. The material was obtained from fine-needle aspiration biopsies and fluid samples. One hundred cases were selected for the research described in the article. The slides were prepared using the Becton Dickinson Totalys SlidePrep device. Based on the research, it was concluded that predominantly the LBC technique gives better results than a conventional smear because the background, which would otherwise make it difficult to assess preparations, was eliminated. Additionally, in LBC preparations the cellularity was increased, and the cells were arranged in a monolayer system, which improves the image quality. The introduction of modifications to the LBC method facilitated the process of sample preparation, without adversely affecting the quality of the obtained material.
{"title":"Assessment of the diagnostic usefulness of liquid-based cytology. The impact of modifications.","authors":"Andrzej Marszałek, Joanna Bakinowska, Małgorzata Grobelna, Adam Śliwiński","doi":"10.5114/pjp.2023.134320","DOIUrl":"10.5114/pjp.2023.134320","url":null,"abstract":"<p><p>The technique of liquid-based cytology (LBC) is of increasing diagnostic value in non-gynecological cytology. The purpose of the present study was to validate modifications to stages of the LBC process and to assess the diagnostic usefulness of the LBC technique. Between May 2021 and January 2022, a total of 484 samples were prepared from routine cytology tests carried out in the Department of Tumor Pathology of The Greater Poland Cancer Center. The material was obtained from fine-needle aspiration biopsies and fluid samples. One hundred cases were selected for the research described in the article. The slides were prepared using the Becton Dickinson Totalys SlidePrep device. Based on the research, it was concluded that predominantly the LBC technique gives better results than a conventional smear because the background, which would otherwise make it difficult to assess preparations, was eliminated. Additionally, in LBC preparations the cellularity was increased, and the cells were arranged in a monolayer system, which improves the image quality. The introduction of modifications to the LBC method facilitated the process of sample preparation, without adversely affecting the quality of the obtained material.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 4","pages":"271-281"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140112001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandra Sejda, Teresa Wierzba-Bobrowicz, Sławomir Michalak, Dariusz Adamek, Jacek Gulczyński, Maciej Ciołkowski, Wiesława Grajkowska, Ewa Iżycka-Świeszewska
Neuropathological central nervous system (CNS) post-mortem examination is a highly specialistic element of the autopsy procedure with methodological specificity. Herein we propose updated recommendations for CNS autopsy for pathologists and neuropathologists. The protocol includes the compendium of neuroanatomy with current nomenclature, consecutive steps of gross examination, as well as appropriate sampling algorithms in different clinical and pathological settings. The significance of pathoclinical cooperation in differential diagnosis is exposed. We believe it is essential to create and promote the guidelines to improve the quality of CNS post-mortem examination at the national level.
{"title":"Recommendations of the Polish Association of Neuropathologists on performing post-mortem examination of the brain and spinal cord.","authors":"Aleksandra Sejda, Teresa Wierzba-Bobrowicz, Sławomir Michalak, Dariusz Adamek, Jacek Gulczyński, Maciej Ciołkowski, Wiesława Grajkowska, Ewa Iżycka-Świeszewska","doi":"10.5114/pjp.2023.127231","DOIUrl":"https://doi.org/10.5114/pjp.2023.127231","url":null,"abstract":"<p><p>Neuropathological central nervous system (CNS) post-mortem examination is a highly specialistic element of the autopsy procedure with methodological specificity. Herein we propose updated recommendations for CNS autopsy for pathologists and neuropathologists. The protocol includes the compendium of neuroanatomy with current nomenclature, consecutive steps of gross examination, as well as appropriate sampling algorithms in different clinical and pathological settings. The significance of pathoclinical cooperation in differential diagnosis is exposed. We believe it is essential to create and promote the guidelines to improve the quality of CNS post-mortem examination at the national level.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 1","pages":"1-11"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9612863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vulval tumours are rare, representing merely 4% of all gynaecological neoplasms. 98% of vulvar lesions are benign, and only 2% are malignant. Of all vulvar malignancies, while squamous cell carcinoma is the most common malignancy, leiomyosarcomas of the vulva are extremely rare. Usually these tumours have nonspecific clinical manifestations, often leading to misdiagnoses of Bartholin cysts or abscesses. We describe a case of a 47-year-old woman who presented with a nonspecific painless swelling in the left vulva for 2 months which was diagnosed as leiomyosarcoma of the vulva on biopsy as well as resection.
{"title":"Primary leiomyosarcoma of the vulva - a rare occurrence.","authors":"Ruchi Rathore, Anju Singh, Neerja Bhatla, Sandeep Mathur","doi":"10.5114/pjp.2023.127293","DOIUrl":"https://doi.org/10.5114/pjp.2023.127293","url":null,"abstract":"<p><p>Vulval tumours are rare, representing merely 4% of all gynaecological neoplasms. 98% of vulvar lesions are benign, and only 2% are malignant. Of all vulvar malignancies, while squamous cell carcinoma is the most common malignancy, leiomyosarcomas of the vulva are extremely rare. Usually these tumours have nonspecific clinical manifestations, often leading to misdiagnoses of Bartholin cysts or abscesses. We describe a case of a 47-year-old woman who presented with a nonspecific painless swelling in the left vulva for 2 months which was diagnosed as leiomyosarcoma of the vulva on biopsy as well as resection.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 1","pages":"56-58"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Coronavirus disease 2019 (COVID-19) has caused respiratory system diseases and affected people's access to healthcare services for diseases other than COVID-19. After the COVID-19 pandemic, changes occurred in the number and content of pathology laboratory samples, related to measures such as reducing the number of outpatient clinics in hospitals, postponing elective surgery, and restricting cancer screening. All samples sent to the pathology laboratory between 2019 and 2020 were included in our study. Biopsy, cytology, histochemical, and immunohistochemical staining and biopsies for malignant cases were evaluated. Changes in sample number and content caused by the pandemic were examined. The number of biopsies was 24 312 in 2019 and 13 208 in 2020. On comparison, a decrease was observed in all parameters. The largest (78.5%) and smallest (11.02%) decreases were observed in examinations of the incoming preparations for consultation (214-46) and Trucut needle biopsies (726-646), respectively. Cases such as appendectomies that require urgent intervention and malignancies that require further examination and diagnosis are the least affected. However, whether the decrease in cancer screening will affect the early diagnosis and treatment of malignancies and create a public health problem in the future remains to be established.
{"title":"Comparison of the number and content of pathology laboratory samples before and after the COVID-19 pandemic.","authors":"Leymune Parlak, Emine Zeynep Tarini","doi":"10.5114/pjp.2023.128964","DOIUrl":"https://doi.org/10.5114/pjp.2023.128964","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has caused respiratory system diseases and affected people's access to healthcare services for diseases other than COVID-19. After the COVID-19 pandemic, changes occurred in the number and content of pathology laboratory samples, related to measures such as reducing the number of outpatient clinics in hospitals, postponing elective surgery, and restricting cancer screening. All samples sent to the pathology laboratory between 2019 and 2020 were included in our study. Biopsy, cytology, histochemical, and immunohistochemical staining and biopsies for malignant cases were evaluated. Changes in sample number and content caused by the pandemic were examined. The number of biopsies was 24 312 in 2019 and 13 208 in 2020. On comparison, a decrease was observed in all parameters. The largest (78.5%) and smallest (11.02%) decreases were observed in examinations of the incoming preparations for consultation (214-46) and Trucut needle biopsies (726-646), respectively. Cases such as appendectomies that require urgent intervention and malignancies that require further examination and diagnosis are the least affected. However, whether the decrease in cancer screening will affect the early diagnosis and treatment of malignancies and create a public health problem in the future remains to be established.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 2","pages":"131-135"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mesothelioma is a locally aggressive malignant tumor that arises on the mesothelial surfaces of the pleura, peritoneum and tunica vaginalis. There are three histologic subtypes of mesothelioma: epithelioid, biphasic, and sarcomatoid. Pleural mesothelioma is usually characterized by diffuse pleural thickening. Disease progression is characterized by local invasion of the chest wall and lung. Lymphatic metastasis is rare and hematogenous metastasis is much rarer. The purpose of these case reports is to emphasize that pleural mesothelioma metastases can occur in unexpected places and to contribute to the literature.
{"title":"Pleural mesothelioma metastasis of the scalp.","authors":"Tugcem Bicak, Selver Ozekinci, İbrahim İbiloğlu","doi":"10.5114/pjp.2023.134322","DOIUrl":"10.5114/pjp.2023.134322","url":null,"abstract":"<p><p>Mesothelioma is a locally aggressive malignant tumor that arises on the mesothelial surfaces of the pleura, peritoneum and tunica vaginalis. There are three histologic subtypes of mesothelioma: epithelioid, biphasic, and sarcomatoid. Pleural mesothelioma is usually characterized by diffuse pleural thickening. Disease progression is characterized by local invasion of the chest wall and lung. Lymphatic metastasis is rare and hematogenous metastasis is much rarer. The purpose of these case reports is to emphasize that pleural mesothelioma metastases can occur in unexpected places and to contribute to the literature.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 4","pages":"297-301"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140112007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dominik Pruski, Sonja Millert-Kalińska, Radosław Mądry, Klaudia Kotynia, Tadeusz Pawełek, Damian Rusek, Andrzej Zmaczyński, Robert Jach, Marcin Przybylski
Leiomyosarcoma is one of the most common types of soft tissue sarcoma in adults, and it can occur in almost any part of the body. Uterine leiomyosarcoma constitutes 1% of all gynaecological tumours. Most diagnosed sarcomas are not even suspected before surgery. However, in recent years, awareness of their presence in society has increased. Our case aims to draw attention to the need for better cooperation between pathologists and clinicians and reduce the time from suspicion of the disease to final diagnosis.
{"title":"Uterine sarcoma - time is worth its weight in gold.","authors":"Dominik Pruski, Sonja Millert-Kalińska, Radosław Mądry, Klaudia Kotynia, Tadeusz Pawełek, Damian Rusek, Andrzej Zmaczyński, Robert Jach, Marcin Przybylski","doi":"10.5114/pjp.2023.127292","DOIUrl":"https://doi.org/10.5114/pjp.2023.127292","url":null,"abstract":"<p><p>Leiomyosarcoma is one of the most common types of soft tissue sarcoma in adults, and it can occur in almost any part of the body. Uterine leiomyosarcoma constitutes 1% of all gynaecological tumours. Most diagnosed sarcomas are not even suspected before surgery. However, in recent years, awareness of their presence in society has increased. Our case aims to draw attention to the need for better cooperation between pathologists and clinicians and reduce the time from suspicion of the disease to final diagnosis.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 1","pages":"59-62"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Obg-like ATPase 1 (OLA1) is a member of the Obg family of P-loop NTPases and has recently been detected in several human cancer cells. However, its expression type and clinical relevance in gastric cancer remains unclear. In the present study, mRNA level of OLA1 in gastric cancer (GC) was detected in 2 datasets downloaded from the open Gene Expression Omnibus database and 30 cancer tissues. Immunohistochemistry was performed on GC and its association with Snail in 334 GC patients. The results showed that OLA1 mRNA and protein were elevated in GC tissues. High expression of OLA1 was significantly associated with aggressive features, such as tumour size, lymph-node-metastasis and tumour-nodus-metastases stage ( p = 0.0146, p = 0.0037, p < 0.001, respectively). Moreover, high levels of OLA1 predicted worse overall survival. Multivariate Cox regression analysis indicated that high expression of OLA1 was an independent prognostic factor for poor overall survival ( p = 0.009). Additionally, OLA1 expression was positively correlated with Snail, and a combination of them revealed improved prognostic accuracy for GC patients. High expression of OLA1 predicts poor prognosis in GC patients and may be serviced as a novel target for GC.
Obg样atp酶1 (OLA1)是p环NTPases的Obg家族成员,最近在几种人类癌细胞中被检测到。然而,其在胃癌中的表达类型及临床意义尚不清楚。本研究通过从open Gene Expression Omnibus数据库下载的2个数据集和30个癌组织中检测胃癌(GC)中OLA1的mRNA水平。对334例胃癌患者行免疫组化检测胃癌及其与蜗牛的关系。结果显示,GC组织中OLA1 mRNA和蛋白表达升高。OLA1的高表达与肿瘤大小、淋巴结转移和肿瘤结节转移分期等侵袭性特征显著相关(p = 0.0146, p = 0.0037, p < 0.001)。此外,高水平的OLA1预示着更差的总生存期。多因素Cox回归分析显示,OLA1高表达是总生存差的独立预后因素(p = 0.009)。此外,OLA1表达与Snail呈正相关,两者结合表明胃癌患者的预后准确性有所提高。OLA1的高表达预示着胃癌患者预后不良,可能成为胃癌治疗的新靶点。
{"title":"Clinicopathological significance of Obg-like ATPase 1 and its association with Snail in gastric cancer.","authors":"Juan Wang, Qinghua Cao, Zhiqing Wang","doi":"10.5114/pjp.2023.127265","DOIUrl":"https://doi.org/10.5114/pjp.2023.127265","url":null,"abstract":"<p><p>Obg-like ATPase 1 (OLA1) is a member of the Obg family of P-loop NTPases and has recently been detected in several human cancer cells. However, its expression type and clinical relevance in gastric cancer remains unclear. In the present study, mRNA level of OLA1 in gastric cancer (GC) was detected in 2 datasets downloaded from the open Gene Expression Omnibus database and 30 cancer tissues. Immunohistochemistry was performed on GC and its association with Snail in 334 GC patients. The results showed that OLA1 mRNA and protein were elevated in GC tissues. High expression of OLA1 was significantly associated with aggressive features, such as tumour size, lymph-node-metastasis and tumour-nodus-metastases stage ( p = 0.0146, p = 0.0037, p < 0.001, respectively). Moreover, high levels of OLA1 predicted worse overall survival. Multivariate Cox regression analysis indicated that high expression of OLA1 was an independent prognostic factor for poor overall survival ( p = 0.009). Additionally, OLA1 expression was positively correlated with Snail, and a combination of them revealed improved prognostic accuracy for GC patients. High expression of OLA1 predicts poor prognosis in GC patients and may be serviced as a novel target for GC.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 1","pages":"42-50"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CD98 is a marker of cancer stem cells, and it regulates radiosensitivity in head and neck squamous cell carcinoma (HNSCC). The current study aimed to investigate whether CD98 can be used as a prognostic factor and marker of radioresistance. CD98 immunostaining was performed using biopsy specimens collected from patients diagnosed with HNSCC. The average period of postoperative monitoring was 31.6 months. The treatment options were radiation therapy with either cisplatin or cetuximab, and surgery. The participants were divided into groups of low and high fluorescence intensity. CD98 was an independent prognostic factor of radioresistance. In total, 103 patients were treated with chemoradiotherapy or bioradiotherapy. The overall survival rates of patients receiving chemoradiotherapy or bioradiotherapy were 69.2% in the low group and 36.2% in the high group. The progression-free survival rates were 60.0% and 24.6%, respectively. CD98 expression was considered an independent prognostic factor of overall survival and progression-free survival. In total, 99 patients underwent surgical treatment. The surgery group did not differ according to CD98 expression. Via CD98 immunostaining, sensitivity to radiotherapy can be determined in advance. In HNSCC, knowledge about sensitivity to radiotherapy can significantly improve prognosis.
{"title":"CD98 expression can be a predictive factor of resistance to radiotherapy in head and neck squamous cell carcinoma.","authors":"Hitomi Suzuki, Yohei Kawasaki, Shinsuke Suzuki, Takechiyo Yamada, Ayumi Ito, Maya Suzuki, Masahito Miura, Haruka Hatakeyama, Yasufumi Omori","doi":"10.5114/pjp.2023.128695","DOIUrl":"https://doi.org/10.5114/pjp.2023.128695","url":null,"abstract":"<p><p>CD98 is a marker of cancer stem cells, and it regulates radiosensitivity in head and neck squamous cell carcinoma (HNSCC). The current study aimed to investigate whether CD98 can be used as a prognostic factor and marker of radioresistance. CD98 immunostaining was performed using biopsy specimens collected from patients diagnosed with HNSCC. The average period of postoperative monitoring was 31.6 months. The treatment options were radiation therapy with either cisplatin or cetuximab, and surgery. The participants were divided into groups of low and high fluorescence intensity. CD98 was an independent prognostic factor of radioresistance. In total, 103 patients were treated with chemoradiotherapy or bioradiotherapy. The overall survival rates of patients receiving chemoradiotherapy or bioradiotherapy were 69.2% in the low group and 36.2% in the high group. The progression-free survival rates were 60.0% and 24.6%, respectively. CD98 expression was considered an independent prognostic factor of overall survival and progression-free survival. In total, 99 patients underwent surgical treatment. The surgery group did not differ according to CD98 expression. Via CD98 immunostaining, sensitivity to radiotherapy can be determined in advance. In HNSCC, knowledge about sensitivity to radiotherapy can significantly improve prognosis.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 2","pages":"122-130"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrzej Marszałek, Agata Kubicka, Inga Jagiełło, Anna Malicka-Durczak
The HER2 gene is a biomarker for breast cancer prognosis and treatment. Overexpression of HER2 protein determined by immunohistochemistry (IHC) or amplification of the HER2 gene determined by fluorescence in situ hybridization (FISH) is a condition for qualifying patients for anti-HER2 therapy. Due to the high toxicity of anti-HER2 treatment, proper patient selection is essential. In our study we compared 40 cases with IHC staining of HER2 antibody determined by Ventana PATHWAY anti-HER2/neu antibody (4B5) as HER2 2+ with the new antibody (HercepTest™ mAb PharmDx [Dako Omnis] [GE001]). Then using a double-blind study we compared the (IHC) evaluation with FISH results. In 65% of cases (26/40) the IHC 2+ score remained unchanged, in 32.5% of cases (13/40) expression of HER2 protein after IHC with new antibody was indicated as 3+ score, and in one case we observed a decrease of HER2 protein expression to 1+. In all cases but one, in which we found IHC HER 3+ with new antibody, there was FISH amplification. We have reason to believe that the new antibody will reduce the diagnostic time and avoid unnecessary costs. Due to the small study group, further investigation is needed.
HER2基因是癌症预后和治疗的生物标志物。通过免疫组织化学(IHC)测定的HER2蛋白的过度表达或通过荧光原位杂交(FISH)测定的HER2基因的扩增是使患者有资格接受抗HER2治疗的条件。由于抗HER2治疗的高毒性,正确的患者选择至关重要。在我们的研究中,我们比较了40例通过Ventana PATHWAY抗HER2/neu抗体(4B5)确定为HER2+的HER2抗体的IHC染色与新抗体(HercepTest™ mAb PharmDx[Dako Omnis][GE001])。然后使用双盲研究,我们将(IHC)评估与FISH结果进行了比较。在65%的病例(26/40)中,IHC 2+评分保持不变,在32.5%的病例(13/40)中,用新抗体进行IHC后HER2蛋白的表达显示为3+评分,在一个病例中,我们观察到HER2蛋白表达降至1+。在除一例外的所有病例中,我们发现了带有新抗体的IHC HER3+,均存在FISH扩增。我们有理由相信,新抗体将缩短诊断时间,避免不必要的成本。由于研究小组规模较小,需要进一步调查。
{"title":"Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis.","authors":"Andrzej Marszałek, Agata Kubicka, Inga Jagiełło, Anna Malicka-Durczak","doi":"10.5114/pjp.2023.129352","DOIUrl":"https://doi.org/10.5114/pjp.2023.129352","url":null,"abstract":"<p><p>The HER2 gene is a biomarker for breast cancer prognosis and treatment. Overexpression of HER2 protein determined by immunohistochemistry (IHC) or amplification of the HER2 gene determined by fluorescence in situ hybridization (FISH) is a condition for qualifying patients for anti-HER2 therapy. Due to the high toxicity of anti-HER2 treatment, proper patient selection is essential. In our study we compared 40 cases with IHC staining of HER2 antibody determined by Ventana PATHWAY anti-HER2/neu antibody (4B5) as HER2 2+ with the new antibody (HercepTest™ mAb PharmDx [Dako Omnis] [GE001]). Then using a double-blind study we compared the (IHC) evaluation with FISH results. In 65% of cases (26/40) the IHC 2+ score remained unchanged, in 32.5% of cases (13/40) expression of HER2 protein after IHC with new antibody was indicated as 3+ score, and in one case we observed a decrease of HER2 protein expression to 1+. In all cases but one, in which we found IHC HER 3+ with new antibody, there was FISH amplification. We have reason to believe that the new antibody will reduce the diagnostic time and avoid unnecessary costs. Due to the small study group, further investigation is needed.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":"74 2","pages":"82-88"},"PeriodicalIF":0.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}